RxDoctor Payments Data

Emily Schorr, MD

Neurology · San Diego, CANPI 1255862041

Payments from drug & device makers

$7,343in general payments, 2019–2025

Across 35 payments — averaging $209.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$6K
  • TG Therapeutics, Inc.$402
  • Novartis$323
  • EMD Serono, Inc.$269
  • AstraZeneca$195
  • Biogen$158
  • plus $145 from 4 others

What the payments were for

  • Consulting fees$5,50075%
  • Food & beverage$1,64822%
  • Education$1953%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)11$5,852
TG Therapeutics, Inc.5$402
Novartis5$323
EMD Serono, Inc.2$269
AstraZeneca3$195
Biogen4$158
Lilly USA, LLC1$58
Pfizer2$47
AbbVie1$25
Genentech USA, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,343 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$42,442
Medicare patients
137
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate18$103,130
QuliptaAtogepant13$14,282
UbrelvyUbrogepant12$13,931
Emgality PenGalcanezumab-Gnlm11$7,635
Dalfampridine ErDalfampridine39$7,453
Gabapentin46$804
Baclofen26$565
Duloxetine Hcl15$437
Levetiracetam16$428
Pregabalin20$339
RizatriptanRizatriptan Benzoate13$184
Tizanidine Hcl11$131
Diazepam17$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$25$28,21325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →